Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study

Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study

(2018) François Montastruc et al.   RHEUMATOLOGY

Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice

(2017) Hjalmar Wadström et al.   JAMA Internal Medicine

Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased?

(2017) K. Hellgren et al.   Arthritis & Rheumatology

The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis

(2016) Lucía Silva-Fernández et al.   RHEUMATOLOGY

Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

(2014) Louise K Mercer et al.   ANNALS OF THE RHEUMATIC DISEASES

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

(2014) Paul Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Smoking and Rheumatoid Arthritis

(2014) Kathleen Chang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Long-Term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment

(2014) Rieke Alten et al.   Arthritis & Rheumatology

Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program

(2013) M. E. Weinblatt et al.   JOURNAL OF RHEUMATOLOGY

Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow-up study from the DANBIO Registry

(2012) Lene Dreyer et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy

(2012) Maria A. Lopez-Olivo et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy

(2012) MARK C. GENOVESE et al.   JOURNAL OF RHEUMATOLOGY

Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial

(2011) J. M. Kremer et al.   ANNALS OF THE RHEUMATIC DISEASES

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data

(2010) Johan Askling et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT

(2010) Anja Strangfeld et al.   ARTHRITIS RESEARCH & THERAPY

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)

(2009) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIB Study

(2009) R. WESTHOVENS et al.   JOURNAL OF RHEUMATOLOGY

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

(2008) M Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES

A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis

(2008) Allison L Smitten et al.   ARTHRITIS RESEARCH & THERAPY

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

(2007) M Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES